K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · EXELIXIS INC.
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-05-07 | EXEL | EXELIXIS INC. | W STRATEGIES, LLC | $0 | Education about access to prescription drugs. |
| 2026-04-20 | EXEL | EXELIXIS INC. | EXELIXIS INC. | $520K | Proposals related to drug pricing including the Administrations Most-Favored-Nation Prescription Drug Pricing proposal, implementation of drug-related provisions of the Inflation Reduction Act, and administration of the 340B Drug Pricing Program. PBM reform proposals. The Help Ensure Lower Patient (HELP) Copays Act. Intellectual property proposals relating to life sciences. S.1930/HR 3731, Small Biotech Innovation Act. Health agency funding levels. IRC Section 174 amortization of R&D expenditures. |
| 2026-04-20 | EXEL | EXELIXIS INC. | ARNOLD & PORTER KAYE SCHOLER LLP | $60K | Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731). Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. |
| 2026-04-20 | EXEL | EXELIXIS INC. | TODD STRATEGY GROUP | $50K | Policy to advance pharmaceutical research and development. 340B. Implementation of Inflation Reduction Act of 2022. Intellectual property. |
| 2026-04-17 | EXEL | EXELIXIS INC. | LMH STRATEGIC SOLUTIONS | $30K | Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. |
| 2026-01-20 | EXEL | EXELIXIS INC. | EXELIXIS INC. | $510K | Proposals related to drug pricing including the Administrations Most-Favored-Nation Prescription Drug Pricing proposal, implementation of drug-related provisions of the Inflation Reduction Act, and administration of the 340B Drug Pricing Program. PBM reform proposals. The Help Ensure Lower Patient (HELP) Copays Act. Intellectual property proposals relating to life sciences. S.1930/HR 3731, Small Biotech Innovation Act. Health agency funding levels. IRC Section 174 amortization of R&D expenditures. |
| 2026-01-20 | EXEL | EXELIXIS INC. | EXELIXIS INC. | $500K | IRC Section 174 amortization of R&D expenditures. Proposals related to drug pricing including the Administrations Most-Favored-Nation Prescription Drug Pricing proposal, implementation of drug-related provisions of the Inflation Reduction Act, and administration of the 340B Drug Pricing Program. PBM reform proposals. The Help Ensure Lower Patient (HELP) Copays Act. Intellectual property proposals relating to life sciences. S.1930/HR 3731, Small Biotech Innovation Act. Health agency funding levels. |
| 2026-01-20 | EXEL | EXELIXIS INC. | TODD STRATEGY GROUP | $50K | Policy to advance pharmaceutical research and development. 340B. Implementation of Inflation Reduction Act of 2022. Intellectual property. |
| 2026-01-16 | EXEL | EXELIXIS INC. | ARNOLD & PORTER KAYE SCHOLER LLP | $60K | Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731). Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. |
| 2026-01-12 | EXEL | EXELIXIS INC. | LMH STRATEGIC SOLUTIONS | $30K | Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. |
| 2025-10-20 | EXEL | EXELIXIS INC. | EXELIXIS INC. | $500K | Proposals related to drug pricing including the Administrations Most-Favored-Nation Prescription Drug Pricing proposal, implementation of drug-related provisions of the Inflation Reduction Act, and administration of the 340B Drug Pricing Program. PBM reform proposals. The Help Ensure Lower Patient (HELP) Copays Act. Intellectual property proposals relating to life sciences. S.1930/HR 3731, Small Biotech Innovation Act. Health agency funding levels. IRC Section 174 amortization of R&D expenditures. |
| 2025-10-20 | EXEL | EXELIXIS INC. | LMH STRATEGIC SOLUTIONS | $30K | Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. |
| 2025-10-16 | EXEL | EXELIXIS INC. | ARNOLD & PORTER KAYE SCHOLER LLP | $60K | Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731). Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Issues related to biopharmaceutical intellectual property and patent matters. |
| 2025-10-12 | EXEL | EXELIXIS INC. | TODD STRATEGY GROUP | $50K | Policy to advance pharmaceutical research and development. 340B. Implementation of Inflation Reduction Act of 2022. Intellectual property. |
| 2025-07-21 | EXEL | EXELIXIS INC. | EXELIXIS INC. | $480K | Proposals related to drug pricing including the Administrations Most-Favored-Nation Prescription Drug Pricing proposal, implementation of drug-related provisions of the Inflation Reduction Act, and administration of the 340B Drug Pricing Program. PBM reform proposals. The Help Ensure Lower Patient (HELP) Copays Act. Intellectual property proposals relating to life sciences. S.1930/HR 3731, Small Biotech Innovation Act. Health agency funding levels. IRC Section 174 amortization of R&D expenditures. |
| 2025-07-19 | EXEL | EXELIXIS INC. | TODD STRATEGY GROUP | $50K | Policy to advance pharmaceutical research and development. 340B. Implementation of Inflation Reduction Act of 2022. Intellectual property. |
| 2025-07-17 | EXEL | EXELIXIS INC. | ARNOLD & PORTER KAYE SCHOLER LLP | $60K | Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731). Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Issues related to biopharmaceutical intellectual property and patent matters. Issues related to research and development (R&D) tax credits. |
| 2025-07-15 | EXEL | EXELIXIS INC. | LMH STRATEGIC SOLUTIONS | $0 | Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. |
| 2025-04-21 | EXEL | EXELIXIS INC. | TODD STRATEGY GROUP | $50K | Policy to advance pharmaceutical research and development. 340B. Implementation of Inflation Reduction Act of 2022. Intellectual property. |
| 2025-04-18 | EXEL | EXELIXIS INC. | EXELIXIS INC. | $460K | Proposals related to drug pricing, including implementation of related provisions of the Inflation Reduction Act. Administration of the 340B Drug Pricing Program. PBM reform proposals. The Help Ensure Lower Patient (HELP) Copays Act. Intellectual property proposals relating to life sciences. Reintroduction of the Small Biotech Innovation Act. Health agency funding levels. IRC Section 174 amortization of R&D expenditures. |
| 2025-04-18 | EXEL | EXELIXIS INC. | ARNOLD & PORTER KAYE SCHOLER LLP | $60K | Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029, 118th Congress). Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Issues related to biopharmaceutical intellectual property and patent matters. Issues related to research and development (R&D) tax credits. |
| 2025-01-21 | EXEL | EXELIXIS INC. | EXELIXIS INC. | $460K | Proposals related to drug pricing, including implementation of related provisions of the Inflation Reduction Act. Administration of the 340B Drug Pricing Program. PBM reform proposals. The Help Ensure Lower Patient (HELP) Copays Act. Intellectual property proposals relating to life sciences. S.5028, The Small Business Biotech Act. IRC Section 174 amortization of R&D expenditures |
| 2025-01-21 | EXEL | EXELIXIS INC. | TODD STRATEGY GROUP | $50K | Policy to advance pharmaceutical research and development. 340B. Implementation of Inflation Reduction Act of 2022. Intellectual property. |